# Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

> **NCT06258668** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 505 (estimated)

## Conditions studied

- Moderate-to-severe Plaque Psoriasis

## Interventions

- **DRUG:** Deucravacitinib

## Key facts

- **NCT ID:** NCT06258668
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 505 (ESTIMATED)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06258668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06258668, "Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06258668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*